



September 18, 2020  
Gene Techno Science Co., Ltd.  
Code: 4584 (TSE Mothers)  
Masaharu Tani, President & CEO

## **Announcement of Application for Approval of Manufacturing and Sales in Japan for biosimilar in the Ophthalmic Area**

Tokyo, September 18, 2020 – Gene Techno Science Co., Ltd. (“GTS”) has been collaborating with Senju Pharmaceutical Co., Ltd. based on the joint development agreement for the biosimilar in the ophthalmic area (Project name: GBS-007) executed on May 12, 2016, and Senju Pharmaceutical Co., Ltd. applied for approval of manufacturing and sales in Japan to the Ministry of Health, Labour and Welfare on September 18, 2020.

The impact on the business results for the fiscal year ending March 2021 is expected to be minimal.

### About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

### **Contact:**

Gene Techno Science Co., Ltd.  
Tel: +81-3-6222-9547 Mail: [info@g-gts.com](mailto:info@g-gts.com)